The “exploratory, dose ranging study” is the phase-2 RA study whose extension (testing a higher dose) is still in progress. The immediately following sentence in the PR clarifies the context.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”